Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in

Riccardo Masetti1,2, Davide Leardini1, Edoardo Muratore1

  • 1Pediatric Oncology and Hematology "Lalla Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Blood
|October 19, 2023
PubMed

Insights

Gut microbiota diversity in children undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) impacts survival. Higher gut microbial diversity before allo-HSCT is linked to better survival and reduced acute graft-versus-host disease.

Area of Science:

  • Microbiology
  • Pediatric Hematology/Oncology
  • Immunology

Background:

  • The link between gut microbiota diversity and survival post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) is established in adults.
  • Its relevance in pediatric allo-HSCT recipients remains less understood.

Purpose of the Study:

  • To investigate the association between gut microbiota diversity and clinical outcomes in pediatric allo-HSCT patients.
  • To explore the correlation between gut microbial composition and the incidence of acute graft-versus-host disease (aGVHD).

Main Methods:

  • Analysis of stool samples from 90 pediatric allo-HSCT recipients using 16S rRNA sequencing.
  • Estimation of gut microbiota diversity via the Shannon index and ecological structure using networking approaches.
  • Stratification of patients into higher- and lower-diversity groups pre-transplant and at engraftment.

Main Results:

  • Higher gut microbiota diversity pre-transplant correlated with significantly improved overall survival (88.9% vs 62.7%, P=.011) and lower incidence of severe aGVHD.
  • No significant difference in relapse-free survival was observed between diversity groups (P=.091).
  • Specific microbial families (e.g., Ruminococcaceae, Oscillospiraceae) were enriched in higher-diversity groups, while others (e.g., Enterococcaceae, Enterobacteriaceae) predominated in lower-diversity groups.

Conclusions:

  • Gut microbiota diversity and composition prior to allo-HSCT are critical factors influencing survival and aGVHD development in pediatric patients.
  • Restoring microbial diversity may be a potential therapeutic strategy to improve outcomes in pediatric allo-HSCT.
  • Further research into specific keystone taxa like short-chain fatty acid producers could offer targeted interventions.